arrow
F

Fehmı Tabak

Cerrahpasa Medical Faculty
H指数:41
被引数:8,263

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Shifting epidemiology of bloodstream infections during the pandemic era: a comparative analysis of blood cultures from adult intensive care unit patients

大流行时期血流感染的流行病学变化:对成人重症监护病房患者血培养的对比分析

2026-10-210
OAAI
A National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate

全国多中心研究:慢性乙型肝炎初始抗病毒治疗偏好——恩替卡韦与替诺福韦双磷酸盐的对比

2026-02-010
PRE
Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3

直接抗病毒药物在基因型2和3型丙型肝炎治疗中的真实世界经验

2026-01-010
PRE
Risk Factors for Major Adverse Cardiovascular Events in Antiretroviral Therapy-Treated People with HIV: A Long-Term Cohort Study in Turkey

抗逆转录病毒治疗的人类免疫缺陷病毒感染者发生主要不良心血管事件的风险因素:一项土耳其长期队列研究

2025-07-180
PRE
Assisting the Diagnosis of Cirrhosis in Chronic Hepatitis C Patients Based on Machine Learning Algorithms: A Novel Non-Invasive Approach

基于机器学习算法协助诊断慢性丙型肝炎患者肝硬化:一种新颖的无创方法

2025-05-190
OA
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
2022-05-0135
OAAI
The Role of Obesity in Predicting the Clinical Outcomes of COVID-19
2021-08-056
OAAI